Abg Innovation Capital Partners Iii Gp LTD Castle Biosciences Inc Transaction History
Abg Innovation Capital Partners Iii Gp LTD
- $806,000
- Q1 2024
A detailed history of Abg Innovation Capital Partners Iii Gp LTD transactions in Castle Biosciences Inc stock. As of the latest transaction made, Abg Innovation Capital Partners Iii Gp LTD holds 33,626 shares of CSTL stock, worth $732,038. This represents 92.31% of its overall portfolio holdings.
Number of Shares
33,626
Previous 36,747
8.49%
Holding current value
$732,038
Previous $793,000
6.18%
% of portfolio
92.31%
Previous 93.74%
Shares
3 transactions
Others Institutions Holding CSTL
# of Institutions
162Shares Held
25.3MCall Options Held
82.2KPut Options Held
150K-
Black Rock Inc. New York, NY2.6MShares$56.5 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.55MShares$55.5 Million0.3% of portfolio
-
Granahan Investment Management, LLC Waltham, MA1.63MShares$35.4 Million1.3% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.53MShares$33.4 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.49MShares$32.5 Million0.0% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $572M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...